Cargando…

Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial

BACKGROUND: The Camrelizumab Plus Apatinib in Patients with Advanced Cervical Cancer trial was a single-arm, phase II study that showed promising activity of the programmed death-1 (PD-1) inhibitor camrelizumab plus the vascular endothelial growth factor receptor-2 inhibitor apatinib in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Xin, He, Minjun, Peng, Hongyu, Tong, Chongjie, Liu, Zhimin, Zhang, Xiaolong, Shao, Yang, Zhu, Dongqin, Zhang, Junli, Yin, Jiani C, Yang, Fan, Lan, Chunyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137235/
https://www.ncbi.nlm.nih.gov/pubmed/34011535
http://dx.doi.org/10.1136/jitc-2020-002223